Showcases Stock ranks Forex

Bridgebio Pharma Inc (BBIO)
47  0.87 (1.89%) 10-22 16:00
Open: 46.13 Pre. Close: 46.13
High: 47.02 Low: 45.33
Volume: 481,816 Market Cap: 7,016M
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; collaboration with University of Colorado Anschutz Medical Campus to advance novel research on genetically driven diseases into therapeutic applications for patients; and collaboration with Salk Institute for Biological Studies. The company was founded in 2015 and is headquartered in Palo Alto, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 47.1 - 47.325 47.325 - 47.529
Low: 44.778 - 45.039 45.039 - 45.276
Close: 46.563 - 46.999 46.999 - 47.395
Stock Technical Analysis
Target: Six months: 56.87
One year: 60.69
Support: Support1: 43.41
Support2: 36.12
Resistance: Resistance1: 48.69
Resistance2: 51.96
Pivot: 46.66
Moving Averages: MA(5): 46.71
MA(20): 47.13
MA(100): 54.03
MA(250): 56.57
MACD: MACD(12,26): -0.73
Signal(12,26,9): -0.84
%K %D: %K(14,3): 40.90
%D(3): 42.47
RSI: RSI(14): 46.97
52-Week: High: 73.5
Low: 37.29
Change(%): 18.4
Average Vol(K): 3-Month: 81487
10-Days: 62324
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

BBIO has closed below upper band by 44.0%. Bollinger Bands are 24.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Thu, 21 Oct 2021
BridgeBio Pharma (BBIO) gains 1.61% to Close at $46.13 on October 21 -

Tue, 19 Oct 2021
BridgeBio Pharma (BBIO) falls 1.44% in Light Trading on October 19 -

Mon, 18 Oct 2021
Mizuho Securities Stick to Their Buy Rating for BridgeBio Pharma Inc By -

Mon, 18 Oct 2021
Hedge Funds Are Piling Into BridgeBio Pharma, Inc. (BBIO) - Yahoo Finance

Tue, 12 Oct 2021
BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers - Yahoo Finance

Thu, 07 Oct 2021
BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models - Yahoo Finance

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 149.28
Shares Float (M) 73.14
% Held by Insiders 7.47
% Held by Institutions 96.18
Shares Short (K) 11580
Shares Short Prior Month (K) 11140
Stock Financials
EPS -4.730
Book Value (p.s.) 3.920
Profit Margin
Operating Margin -806.01
Return on Assets (ttm) -31.8
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) 0.055
Sales Per Share 0.420
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -470.42
Levered Free Cash Flow (M) -260.75
Stock Valuation
PE Ratio -9.94
PEG Ratio
Price to Book value 11.99
Price to Sales 111.85
Price to Cash Flow -14.91
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator